| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2901128 | Chest | 2011 | 6 Pages |
Abstract
In this small cohort of patients with moderate to severe pulmonary hypertension in the setting of POPH, we have shown that ambrisentan monotherapy can significantly improve pulmonary hemodynamic responses without adverse effect on hepatic function.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Dr MD, Dr DO, Dr MD, Dr MD, Dr MD, FCCP,